Oxford Biomedica PLC Total Voting Rights (1250E)
November 02 2015 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 1250E
Oxford Biomedica PLC
02 November 2015
Oxford BioMedica
Total Voting Rights
Oxford, UK - 2 November 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), announces that in accordance
with the FCA's Disclosure and Transparency Rule 5.6.1, the Group's
issued share capital as at the close of business on 30 October 2015
consisted of 2,574,040,687 ordinary shares of 1 pence each
("Ordinary Shares"). There are no Ordinary Shares held in
treasury.
Accordingly, the total number of voting rights in Oxford
BioMedica plc at the date of this notice is 2,574,040,687.
The above figure (2,574,040,687) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford BioMedica plc under the FCA's Disclosure
and Transparency Rules.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Group's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Group has licenced products
and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich,
Biogen Idec, Emergent BioSolutions and ImaginAb. Further
information is available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk .
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAEFFEFESFAF
(END) Dow Jones Newswires
November 02, 2015 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024